Blood Pressure Pill Recalled Nationwide After Failing a Lab Test: What Florida Patients Taking Olmesartan, Amlodipine and Hydrochlorothiazide Should Check

A generic three-in-one blood pressure tablet has been recalled nationwide after two lots failed laboratory testing that measures how well the medicine dissolves, according to the U.S. Food and Drug Administration's enforcement report as described by news outlets including First Coast News and WESH. The recall covers 3,744 bottles of olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets in the 40 mg/10 mg/12.5 mg strength, sold by Macleods Pharma USA. For Floridians who take this combination pill, the practical step is simple: check the lot number on the bottle or ask the pharmacy that filled it.

What was recalled

The recall involves two lots, both with an expiration date of May 31, 2027, according to the published recall details:

The FDA's national drug code directory lists both package codes as olmesartan medoxomil, amlodipine and hydrochlorothiazide film-coated tablets, 40 mg/10 mg/12.5 mg, from Macleods Pharmaceuticals Limited, the India-based parent of the U.S. distributor.

The stated reason is failed dissolution specifications. Reports on the recall say the olmesartan component of the affected tablets did not dissolve as required in testing, which could affect how much of the drug the body absorbs. The company began the recall on Oct. 7, and the FDA classified it on Oct. 26, according to those reports. The Florida Press was not able to view the FDA's enforcement database entry directly, and Macleods had not issued a public press release or consumer instructions, according to reports on the recall.

What a Class II recall means

The FDA classified the action as a Class II recall, its middle tier. The agency defines Class II as "a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote."

That is less serious than a Class I recall, which the FDA reserves for situations with a reasonable probability of serious harm or death. In practice, a Class II drug recall generally means the medicine is pulled from pharmacy and wholesale shelves, and patients are not usually told to rush to an emergency room. The concern with a dissolution failure is that a patient may get less blood pressure control than expected from each dose.

A pattern of similar recalls this year

The Macleods action is the latest of several 2026 recalls involving olmesartan and amlodipine combinations, most for the same kind of dissolution failure. FDA enforcement records show these recent actions:

The Ascend products were manufactured by Alkem Laboratories in India, according to the FDA records. The October Ascend recall covers lot 25120696, which expires Dec. 31, 2026, and was distributed nationwide. The Viatris recall, classified as Class III, involved telmisartan content that could exceed specifications. The final row reflects the published details of the Macleods recall.

The records add detail on the earlier actions. Ascend said its October recall was voluntary and firm initiated, began on Oct. 6 and notified customers by letter. Its June recall covered 5 mg/40 mg lot 24123460, which expires Oct. 31, 2027, and its July recall covered 10 mg/20 mg lot 25121311, which expires March 31, 2028. In both, the FDA records cite olmesartan content below specification during dissolution testing. The Viatris telmisartan and amlodipine lots began expiring on Oct. 31, 2026. The FDA defines a Class III recall as one in which use of the product "is not likely to cause adverse health consequences."

How Florida patients can check their medication

Olmesartan is an angiotensin receptor blocker, amlodipine is a calcium channel blocker and hydrochlorothiazide is a diuretic, and the three are combined so patients can take one pill instead of three. Anyone with a prescription for this combination can check the pharmacy label or the manufacturer's bottle for the lot number and the NDC. Pharmacies often transfer tablets into their own bottles, so the lot number may not appear on the label patients see. In that case, the dispensing pharmacy can look up which manufacturer and lot were used to fill the prescription.

Patients whose medication matches one of the recalled lots should contact their pharmacist or doctor about a replacement. Health officials generally advise against stopping a prescribed blood pressure medicine without first talking to a health care provider, since uncontrolled high blood pressure carries its own risks, including stroke and heart attack. Many pharmacies can swap the supply for a different lot or manufacturer of the same drug.

Patients who notice unusual symptoms, such as home blood pressure readings that are higher than normal, should tell their doctor. Problems with any drug can also be reported to the FDA's MedWatch program.

Why this matters in Florida

Florida has one of the oldest populations in the country, and high blood pressure becomes more common with age, so recalls of blood pressure drugs reach a large number of households here. The recalled products were distributed nationwide, and nothing in the published recall details limits them to any region. Combination pills like this one are typically prescribed to patients who need more than one drug to control their blood pressure. Patients who fill prescriptions by mail may never see the manufacturer's original bottle, so calling the mail-order pharmacy is the quickest way to confirm which lot was shipped.

What's next

The FDA monitors a recall until the firm has completed it, and pharmacies may contact affected patients in the coming weeks. The FDA's weekly enforcement report, published each Wednesday, lists new drug recalls as they are classified, and Floridians taking any olmesartan or amlodipine combination product can ask their pharmacist whether their supply is affected by any of this year's recalls.